CyDerm001

CyDerm001 is an exosome-based drug delivery candidate currently in preclinical development by RION. It utilizes the company's proprietary PEP™ (Purified Exosome Product) platform, which consists of exosomes derived from human platelets. CyDerm001 is specifically designed to function as a delivery vehicle for antibiotic cargo, aiming to enhance the targeted transport of antimicrobial agents to specific tissues or pathogens. By leveraging the natural communicative and regenerative properties of platelet-derived exosomes, the CyDerm001 system is intended to improve the therapeutic index of antibiotics, potentially increasing efficacy at the site of infection while minimizing systemic exposure and associated side effects.